Navigation Links
Baron and Budd Supports the Newest Drug Being Tested for Mesothelioma Treatment
Date:8/5/2013

LOS ANGELES (PRWEB) August 05, 2013

Baron and Budd is proud to announce the Food and Drug Administration’s approval of a new drug to be used for the treatment of the rare cancer, mesothelioma, that occurs because of exposure to asbestos. This new drug is called VS-6036, or defactinib, and is a cancer-stem-cell inhibitor that is manufactured by Verastem Inc. (VSTM). (http://online.wsj.com/article/BT-CO-20130724-707069.html?mod=googlenews_wsj)

VS-6036 is being developed thanks to the Food and Drug Administration’s orphan drug designation that assists the development of drugs treating rare conditions affecting 200,000 patients or less within the U.S. With this designation, VS-6036 has been given assistance from the Food and Drug Administration in clinical trial development, pardon from the standard Food and Drug Administration user fees and a seven-year market exclusivity period after approval. (http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/default.htm)

Up to 400 patients are planned to enroll in clinical trial sites in 11 countries for the VS-6036 clinical study for patients suffering from pleural mesothelioma.

“We are encouraged by the work of the FDA and Verastem Inc. to better the lives of those suffering from mesothelioma," said Russell Budd of Baron and Budd. “While the FDA and Verastem Inc. prepare the VS-6036 clinical trial, we will continue to work to make sure that one day the need for mesothelioma treatment is irrelevant. We believe that a global ban on asbestos is imperative."

To find out more about asbestos exposure, mesothelioma and the road toward banning asbestos use within the United States, visit http://baronandbudd.com/areas-of-practice/mesothelioma-attorney/

Baron and Budd is an active participant in asbestos advocacy and mesothelioma education on a national scale. The law firm supports the National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the countries’ top cancer treatment centers. With financial support from Baron and Budd, the NCCN has been able to produce and distribute a treatment resource detailing the Clinical Guidelines for Mesothelioma, titled the Patient Guidelines for Mesothelioma. Baron and Budd is also a repeat platinum sponsor of an international non-profit organization committed to banning asbestos and assisting patients suffering from mesothelioma, the Asbestos Disease Awareness Organization (ADAO). Baron and Budd was also an inaugural donor to the International Mesothelioma Program (IMP) at Brigham and Women’s Hospital in Boston.

Read the full story at http://www.prweb.com/releases/2013/8/prweb10993175.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. The National Plaintiff’s Law Firm of Baron and Budd Handling Granuflo Recall Lawsuits
2. National Law Firm Baron and Budd Responds to Disproportionate Harm Brought to Women Using Lipitor, According to Study
3. Study Supports Value of Sigmoidoscopy, an Alternative to Colonoscopy
4. Study supports urate protection against Parkinsons disease, hints at novel mechanism
5. Dietary fiber alters gut bacteria, supports gastrointestinal health
6. Narconon Louisiana Supports United Nations International Day Against Drug Abuse and Illicit Trafficking
7. NIDA supports development of combined anti-heroin and HIV vaccine
8. Little evidence supports autism treatment options in adolescents
9. $1.8 million grant supports investigation of psoriasis link to cardiovascular disease
10. John Templeton Foundation grant supports Princeton neuroscientists to study cognitive control
11. Human umbilical cord blood cell co-culture supports embryonic stem cell expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... 06, 2016 , ... GrekTek LLC, ( http://www.grektek.com ) an ... http://kck.st/2g3a1so ) for the HealthyWatch, a new device to help patients manage their ... watch while sharing these events with caregivers in real time. , ...
(Date:12/6/2016)... ... December 06, 2016 , ... Keeping Gift Season Safe, In a season stacked ... and age-appropriate for their recipients. This is the idea behind Safe Toys and Gifts ... items that would make good gifts for children. For companies that produce goods that ...
(Date:12/6/2016)... Overland Park, KS (PRWEB) , ... December 06, 2016 , ... ... online retailers of Mobility Scooters . , Mobility Scooters give freedom to people ... and balance problems. Still others may be facing a long period of rehabilitation after ...
(Date:12/6/2016)... ... December 06, 2016 , ... U.S. Security Associates (USA) was ... for their industry leading training methods that engage their associates and link their ... global elite in employer-sponsored training and development programs. , “The 2017 Training Top ...
(Date:12/5/2016)... ... December 05, 2016 , ... Edward ... to announce the arrival of the newest Sciton laser in January 2017. The ... use tunable non-ablative and ablative wavelengths for exceptional results. Outperforming more traditional lasers, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... YORK , Dec. 5, 2016  Balloon catheter ... catheter, which is inserted into the femoral artery in ... the arm to treat constricted blood vessels. These products ... due to atherosclerosis – deposition of lipid substances in ... balloon catheter market is projected to expand at a ...
(Date:12/5/2016)... Spain Glaucoma Surgery Devices Market Outlook to ... Surgery Devices Market Outlook to 2022", provides key market ... report provides value, in millions of US dollars, volume ... - Canaloplasty Micro Catheters and Glaucoma Drainage Devices. ... data for each of these market segements, and global ...
(Date:12/5/2016)... Dec. 5, 2016  Cornerstone Pharmaceuticals, Inc., a ... data from two Phase I trials evaluating its ... 58th annual meeting of the American Society of ... . The two datasets show encouraging efficacy ... leukemia (AML) and T-cell non-Hodgkin,s lymphoma (T-cell NHL), ...
Breaking Medicine Technology: